# Best Peptides for Growth Hormone Optimization: The Evidence Ranked

> An evidence-first ranking of the GH secretagogues sold for 'growth hormone optimization' — tesamorelin, MK-677, CJC-1295, sermorelin and ipamorelin — separating what raises GH/IGF-1 in humans from what only sounds like it should.

*Published 2026-07-01 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
GH secretagogue peptides reliably raise growth hormone and IGF-1 — and do it more physiologically than injecting recombinant GH. But only **tesamorelin** (Grade A, FDA-approved) and **MK-677** (Grade A biomarker) have that proven in human RCTs, and even MK-677's pivotal trial showed the higher hormones produced *no* gain in strength or function. CJC-1295 (no-DAC) and ipamorelin have no dedicated human optimization trial at all. Every peptide here is prohibited in sport at all times.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7)[18](https://peptidevox.com/#r18)

"Growth hormone optimization" is a wellness and marketing frame, not a recognized disease. In practice it means one thing: instead of injecting exogenous recombinant human GH — which shuts down your own pituitary and floods the body with non-pulsatile GH — you use a **secretagogue** that prompts the pituitary to release its own GH in a more natural, pulsatile pattern, with IGF-1 negative feedback acting as a partial ceiling.[9](https://peptidevox.com/#r9)[15](https://peptidevox.com/#r15) That physiologic rationale is real. The leap the marketing makes — from "raises GH/IGF-1 on a lab report" to "makes a healthy adult leaner, stronger or younger" — is the part that remains largely unproven.[16](https://peptidevox.com/#r16)

*This article is informational and editorial content only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Only tesamorelin is FDA-approved, and only for HIV-associated lipodystrophy; the others are not approved drugs and are sold "for research use only" or compounded. Doses are reported strictly as seen in the literature or labeling, never as a recommendation. Every substance here is prohibited in sport. Decisions about hormones belong with a qualified, licensed clinician.*

## How do these peptides actually raise growth hormone?

GH is released from the anterior pituitary in pulses, mostly during slow-wave sleep, under push-pull control: GHRH from the hypothalamus drives release, somatostatin restrains it, and ghrelin from the stomach amplifies it. GH then acts on the liver and tissues to raise IGF-1, which mediates many of GH's anabolic effects and feeds back to suppress further GH release.[15](https://peptidevox.com/#r15) GH secretion declines with age ("somatopause"), which is the entire premise behind "optimization." The peptides act on different nodes of this circuit.

The **GHRH analogs** — tesamorelin, sermorelin and CJC-1295 — are the "push" lever. They bind the pituitary GHRH receptor (a Gs/cAMP/PKA cascade), increasing GH pulse amplitude while preserving pulsatility, the key physiologic advantage over non-pulsatile rHGH.[9](https://peptidevox.com/#r9) They differ mainly in half-life: sermorelin is short-acting; tesamorelin is DPP-4-stabilized and dosed daily; CJC-1295-with-DAC binds albumin for a 5.8-8.1 day half-life.[9](https://peptidevox.com/#r9) The **ghrelin-receptor agonists** — ipamorelin and MK-677 — are the "amplify" lever, binding GHS-R1a (a Gq/PLC/calcium cascade) on a pathway independent of and parallel to the GHRH receptor, which is why combining a GHRH analog with a ghrelin agonist releases more GH than either alone — a synergy first shown in humans around 1990.[15](https://peptidevox.com/#r15) The crucial caveat: that synergy is documented for *acute GH release*, not for superior clinical outcomes. The secretagogue advantage is a built-in ceiling — because IGF-1 feeds back to suppress GH — but that ceiling is not absolute: tesamorelin still pushed 23 percent of patients above an IGF-1 standard-deviation score of +3 over 52 weeks.[2](https://peptidevox.com/#r2)

## Which GH-optimization peptide has the strongest evidence?

Ranked strictly by the strength of human evidence for GH/IGF-1 optimization, the hierarchy is unambiguous — and it does not match the popularity ranking in fitness circles.

  GH-optimization peptides ranked by human evidence

    PeptideClassBest human evidenceGrade

    TesamorelinGHRH analogMultiple Phase III RCTs + FDA approval (HIV lipodystrophy)A
    MK-677 / IbutamorenOral ghrelin mimetic2-year RCT: raises GH/IGF-1 & lean mass; no strength gainA biomarker / C-D benefit
    CJC-1295 (DAC)Long-acting GHRH analogOne human PK/PD RCT (28-49 days)B
    CJC-1295 (no-DAC)Short GHRH analogNo dedicated human trial — extrapolatedD
    SermorelinGHRH 1-29Prior FDA drug (Geref); dated human GH-stimulation dataB
    IpamorelinSelective GHRPOnly human trial (ileus) failed; no optimization dataB acute / D optimization

**Tesamorelin** is the benchmark — the only secretagogue whose GH/IGF-1 rise and measurable body-composition change (roughly 15-20 percent visceral-fat reduction) are demonstrated in multiple double-blind RCTs and a regulatory approval.[1](https://peptidevox.com/#r1)[4](https://peptidevox.com/#r4) **MK-677** is a fascinating second: its two-year RCT raised 24-hour GH about 1.8-fold and IGF-1 about 1.5-fold to young-adult levels and added roughly 1.1 kg of fat-free mass — yet produced no gain in strength, physical function or quality of life, and worsened insulin sensitivity.[7](https://peptidevox.com/#r7) You can verify that pivotal trial's design and null functional endpoints directly in the journal record at [Annals of Internal Medicine](https://www.acpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003). That single finding — higher IGF-1, no stronger person — is the honest headline of the entire category.[8](https://peptidevox.com/#r8)

Further down, **CJC-1295** splits sharply: the DAC form has one legitimate human PK/PD RCT (GH up 2- to 10-fold, IGF-1 elevated up to 28 days), but the no-DAC "mod GRF 1-29" that people actually stack has no human trial of its own.[9](https://peptidevox.com/#r9)[10](https://peptidevox.com/#r10) **Sermorelin** earns its rank on regulatory pedigree — a real former FDA drug (Geref) with genuine GH-stimulation data — but its adult optimization evidence is thin and pre-2008.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12) **Ipamorelin**, despite being the most popular optimization peptide in practice, ranks last on evidence: its only substantial human trial (intravenous, for postoperative ileus, registered as [NCT01280344](https://clinicaltrials.gov/study/NCT01280344)) missed its endpoints, and there is no human optimization trial of ipamorelin or of the CJC-1295-plus-ipamorelin stack at all.[13](https://peptidevox.com/#r13)[14](https://peptidevox.com/#r14)

## What does the evidence NOT support?

Three claims sit at the center of GH-optimization marketing, and each collapses under the human data. First, that **optimizing GH/IGF-1 makes a healthy adult healthier or younger**. The definitive systematic review of GH in healthy elderly people found only small body-composition changes alongside significantly more soft-tissue edema, arthralgia, carpal tunnel syndrome and a trend to new diabetes, and concluded GH cannot be recommended as anti-aging therapy.[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17) Secretagogues raise GH/IGF-1 more gently than rHGH, but the burden of proof that *this is beneficial* in healthy adults has never been met.

Second, that **higher IGF-1 equals better outcomes**. MK-677 raised IGF-1 yet produced no strength or function gain in its two-year RCT and no benefit in an Alzheimer's trial despite rising IGF-1 — biomarker movement is not clinical benefit.[7](https://peptidevox.com/#r7) If anything, chronically elevated IGF-1 is epidemiologically linked to cancer risk, which is precisely why the tesamorelin label mandates IGF-1 monitoring and requires malignancy to be inactive before use.[2](https://peptidevox.com/#r2) Third, that these are **safe or undetectable in sport**: every GHRH analog and every ghrelin mimetic here is explicitly prohibited at all times under WADA Section S2.2, with validated detection methods in accredited labs.[18](https://peptidevox.com/#r18)[19](https://peptidevox.com/#r19)

## What are the safety, legal and root-cause considerations?

The shared GH-class adverse effects — fluid retention and peripheral edema, arthralgia and myalgia, carpal tunnel syndrome, glucose intolerance and reduced insulin sensitivity, and elevated IGF-1 of uncertain long-term significance — are documented for tesamorelin, MK-677 and GH itself.[2](https://peptidevox.com/#r2)[7](https://peptidevox.com/#r7)[16](https://peptidevox.com/#r16) Glucose is the most consistent real-world downside: MK-677 measurably worsened insulin sensitivity and HbA1c, and tesamorelin tripled the rate of HbA1c reaching 6.5 percent versus placebo — anyone with pre-diabetes or metabolic syndrome is moving the wrong direction.[7](https://peptidevox.com/#r7)[2](https://peptidevox.com/#r2) Because GH and IGF-1 are growth factors, malignancy caution runs across the class.

On legal status in 2026: tesamorelin is FDA-approved (HIV lipodystrophy only); sermorelin was formerly approved (Geref, discontinued 2008) and is now compounded-only; and CJC-1295, ipamorelin and MK-677 are not FDA-approved — all three were placed on the FDA 503A interim Category 2 safety-risk list in 2023, and through 2024-2026 the FDA has worked them through PCAC review, recommending against 503A inclusion for ipamorelin and ibutamoren at the October 2024 meeting. Their legal availability for compounding is unsettled and trending restrictive; the FDA's own bulk-substances list and analyses are the primary references for anyone tracking it, such as the [FDA 503A Category 2 bulk-substances page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks).[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)

**Bottom line.** As a class, GH secretagogues do exactly what they say on the biomarker level, and more physiologically than injecting rHGH. The unresolved, marketing-skipped question is whether elevating GH/IGF-1 in an otherwise-healthy adult produces durable benefit that outweighs the known harms — glucose intolerance, edema, joint pain and theoretical IGF-1-driven neoplasia risk.[16](https://peptidevox.com/#r16)[2](https://peptidevox.com/#r2) From a root-cause lens, the levers that most powerfully restore youthful GH pulsatility — deep slow-wave sleep, resistance training, protein timing and reducing visceral fat — are free, upstream of every peptide here, and the foundation any secretagogue is merely layered on top of. Regulatory facts here are current as of June 2026 and should be re-verified after the pending PCAC review dates.

---
Source: https://peptidevox.com/sexual-hormonal-health/peptides-for-gh-optimization
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt